ProPhase Labs (NASDAQ:PRPH) Shares Pass Above 200-Day Moving Average of $9.77

ProPhase Labs, Inc. (NASDAQ:PRPHGet Rating)’s share price crossed above its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $9.77 and traded as high as $10.68. ProPhase Labs shares last traded at $10.26, with a volume of 51,993 shares.

Analysts Set New Price Targets

A number of equities research analysts recently commented on PRPH shares. StockNews.com downgraded ProPhase Labs from a “strong-buy” rating to a “buy” rating in a report on Thursday, June 30th. TheStreet downgraded ProPhase Labs from a “b” rating to a “c+” rating in a report on Tuesday, August 23rd. Finally, Dawson James downgraded ProPhase Labs from a “neutral” rating to a “sell” rating in a report on Thursday, July 21st.

ProPhase Labs Price Performance

The company has a quick ratio of 3.93, a current ratio of 4.20 and a debt-to-equity ratio of 0.12. The stock has a market capitalization of $164.22 million, a PE ratio of 6.84 and a beta of -0.40. The company has a 50-day moving average of $11.33 and a 200 day moving average of $9.77.

Institutional Trading of ProPhase Labs

Several large investors have recently made changes to their positions in PRPH. Precision Wealth Strategies LLC acquired a new position in ProPhase Labs during the second quarter worth $152,000. Goldman Sachs Group Inc. acquired a new position in ProPhase Labs during the second quarter worth $164,000. Cambridge Investment Research Advisors Inc. acquired a new position in ProPhase Labs during the second quarter worth $168,000. Cubist Systematic Strategies LLC acquired a new position in shares of ProPhase Labs in the 2nd quarter valued at $194,000. Finally, State Street Corp lifted its stake in shares of ProPhase Labs by 14.2% in the 1st quarter. State Street Corp now owns 31,063 shares of the company’s stock valued at $217,000 after purchasing an additional 3,868 shares during the last quarter. 9.75% of the stock is currently owned by hedge funds and other institutional investors.

About ProPhase Labs

(Get Rating)

ProPhase Labs, Inc engages in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements in the United States. The company operates in two segments, Diagnostic Services and Consumer Products. It offers a range of OTC dietary supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster.

See Also

Receive News & Ratings for ProPhase Labs Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs and related companies with MarketBeat.com's FREE daily email newsletter.